47.8K
Downloads
75
Episodes
AllergyTalk is a round-up of the latest in the field of allergy and immunology by the American College of Allergy, Asthma and Immunology. In each bi-monthly episode, hosts Gerald Lee, MD, and Merin Kalangara, MD, invite a guest to discuss key articles reviewed in the current issue of AllergyWatch.
Episodes
Tuesday Jul 23, 2019
Tuesday Jul 23, 2019
For today’s episode we will be reviewing three articles about asthma from the May-June 2019 issue of Allergy Watch:
- Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
https://www.ncbi.nlm.nih.gov/pubmed/30217529 - Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison.
https://www.ncbi.nlm.nih.gov/pubmed/30205189 - Indirect Treatment Comparisons and Biologics
https://www.ncbi.nlm.nih.gov/pubmed/30612667 - Endotypes of severe allergic asthma patients who clinically benefit from anti?IgE therapy
https://www.ncbi.nlm.nih.gov/pubmed/30107059/ - Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma
https://www.ncbi.nlm.nih.gov/pubmed/29301922
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee was on an advisory board for Teva.
Dr. Kalangara has received consulting fees from Astra Zenica.
Dr. Fineman
Speaker: AstraZenca, Boehringer Ingelheim, Shire
Research: Aimmune, DBV, Shire, Regeneron.
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.